药学研究2024，Vol.43Issue(5)：495-503,9.DOI:10.13506/j.cnki.jpr.2024.05.014
CYP2D6、CYP2C19、CYP2B6、SLC6A4、HTR2A基因型和5-羟色胺再摄取抑制剂抗抑郁药:2023年CPIC指南解读
CYP2D6,CYP2C19,CYP2B6,SLC6A4,HTR2A genotypes and serotonin reuptake inhibitor antidepressants:interpretation of the 2023 CPIC guideline
摘要
Abstract
The Clinical Pharmacogenetics Implementation Consortium(CPIC)updated and expanded the 2015 guideline for CYP2D6 and CYP2C19 genotypes and selective serotonin reuptake inhibitors(SSRIs)in 2023,adding CYP2B6,SLC6A4,HTR2A,SNRIs,and 5-HT modulators with SSRI-like activity in the sections related to genotype and drugs.The new guideline also updated the application recommendations for serotonin reuptake inhibitors based on gene polymorphism.This article interprets the relevant content of the guideline,in order to provide reference for the individualized treatment of 5-HT reuptake inhibitors in China.关键词
指南/基因多态性/5-羟色胺再摄取抑制剂/抗抑郁药/解读Key words
Guideline/Genetic polymorphism/Serotonin reuptake inhibitor/Antidepressant/Interpretation分类
医药卫生引用本文复制引用
周长凯,荆凡波,于红霞,曹铭晨,史云燕,刘东华,纪洪艳,邢晓敏,王心怡,李静..CYP2D6、CYP2C19、CYP2B6、SLC6A4、HTR2A基因型和5-羟色胺再摄取抑制剂抗抑郁药:2023年CPIC指南解读[J].药学研究,2024,43(5):495-503,9.基金项目
山东省自然科学基金(No.ZR2022MH069) （No.ZR2022MH069）
山东省医务职工科技创新计划项目(No.SDYWZGKCJH2023095) （No.SDYWZGKCJH2023095）
山东省医学会临床药学科研专项(No.YXH2021ZX010) （No.YXH2021ZX010）
